Digestive Diseases and Sciences

, Volume 63, Issue 4, pp 900–909 | Cite as

Chemoprevention by Probiotics During 1,2-Dimethylhydrazine-Induced Colon Carcinogenesis in Rats

  • Sohini Walia
  • Rozy Kamal
  • D. K. Dhawan
  • S. S. KanwarEmail author
Original Article



Probiotics are believed to have properties that lower the risk of colon cancer. However, the mechanisms by which they exert their beneficial effects are relatively unknown.


To assess the impact of probiotics in preventing induction of colon carcinogenesis in rats.


The rats were divided into six groups viz., normal control, Lactobacillus plantarum (AdF10)-treated, Lactobacillus rhamnosus GG (LGG)-treated, 1,2-dimethylhydrazine (DMH)-treated, L. plantarum (AdF10) + DMH-treated and L. rhamnosus GG (LGG) + DMH-treated. Both the probiotics were supplemented daily at a dose of 2 × 1010 cells per day. DMH at a dose of 30 mg/kg body weight was administered subcutaneously twice a week for the first 4 weeks and then once every week for a duration of 16 weeks. Glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and catalase as protein expression of genes involved in apoptosis were assessed during DMH-induced colon carcinogenesis in rats.


DMH treatment decreased the activity of GSH, GPx, GST, SOD and catalase. However, AdF10 and LGG supplementation to DMH-treated rats significantly increased the activity of these enzymes. Further, DMH treatment revealed alterations in the protein expressions of various genes involved in the p53-mediated apoptotic pathway such as p53, p21, Bcl-2, Bax, caspase-9 and caspase-3, which, however, were shifted towards normal control levels upon simultaneous supplementation with probiotics.


The present study suggests that probiotics can provide protection against oxidative stress and apoptotic-related protein disregulation during experimentally induced colon carcinogenesis.


Probiotics Colon cancer Apoptosis Oxidative stress Animal model 



The authors acknowledges the financial support provided by DST INSPIRE Govt. of India.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.


  1. 1.
    Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.CrossRefPubMedGoogle Scholar
  2. 2.
    Martenson JA Jr, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of Intergroup Protocol 130. J Clin Oncol. 2004;22:3277–3283.CrossRefPubMedGoogle Scholar
  3. 3.
    Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365–378.CrossRefPubMedGoogle Scholar
  4. 4.
    Sanders ME, Guarner F, Guerrant R, et al. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62:787–796.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Ther Adv Gastroenterol. 2010;3:307–319.CrossRefGoogle Scholar
  6. 6.
    Chau I, Cunningham D. Adjuvant therapy in colon cancer—what, when and how? Ann Oncol. 2006;17:1347–1359.CrossRefPubMedGoogle Scholar
  7. 7.
    Thirabunyanon M, Hongwittayakorn P. Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells via synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. Appl Biochem Biotechnol. 2013;169:511–525.CrossRefPubMedGoogle Scholar
  8. 8.
    Walia S, Keshani Sood S, et al. Exhibition of DNA-bioprotective activity by microflora of traditional fermented foods of North-Western Himalayas. Food Res Int. 2014;55:176–180.CrossRefGoogle Scholar
  9. 9.
    Jackson PE, O’Connor PJ, Cooper DP, et al. Associations between tissue-specific DNA alkylation, DNA repair and cell proliferation in the colon and colon tumour yield in mice treated with 1,2-dimethylhydrazine. Carcinogenesis. 2003;24:527–533.CrossRefPubMedGoogle Scholar
  10. 10.
    Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993;90:7915–7922.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinog. 1990;3:188–197.CrossRefPubMedGoogle Scholar
  12. 12.
    del Carmen S, de LeBlanc AM, Miyoshi A. Potential application of probiotics in the prevention and treatment of inflammatory bowel diseases. Ulcers. 2011. Scholar
  13. 13.
    Walia S, Kamal R, Kanwar SS, et al. Cyclooxygenase as a target for chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon cancer. Nutr Cancer. 2015;67:603–611.CrossRefPubMedGoogle Scholar
  14. 14.
    Sourabh A, Kanwar SS, Sharma OP. Antagonistic potential of indigenous bacterial probiotics of Western Himalayas against antibiotic-resistant bacterial pathogens. Curr Sci. 2011;101:1–6.Google Scholar
  15. 15.
    Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99:667–676.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–169.PubMedGoogle Scholar
  17. 17.
    Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys. 1978;186:189–195.CrossRefPubMedGoogle Scholar
  18. 18.
    Luck H. Quantitative determination of catalase activity of biological material. Enzymologia. 1954;17:31–40.PubMedGoogle Scholar
  19. 19.
    Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130–7139.PubMedGoogle Scholar
  20. 20.
    Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Carlburg I, Mannervik B. Glutathione reductase. Methods Enzymol. 1985;113:484–490.CrossRefGoogle Scholar
  22. 22.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.CrossRefPubMedGoogle Scholar
  23. 23.
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685.CrossRefPubMedGoogle Scholar
  24. 24.
    Newell LE, Heddle JA. The potent colon carcinogen, 1,2-dimethylhydrazine induces mutations primarily in the colon. Mutat Res. 2004;564:1–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Saini MK, Kaur J, Sharma P, et al. Chemopreventive response of diclofenac, a non-steroidal anti-inflammatory drug in experimental carcinogenesis. Nutr Hosp. 2009;24:717–723.Google Scholar
  26. 26.
    Mano T, Sinohara R, Sawai Y, et al. Changes in lipid peroxidation and free radical scavengers in the brain of hyper-and hypothyroid aged rats. J Endocrinol. 1995;147:361–365.CrossRefPubMedGoogle Scholar
  27. 27.
    Huang YL, Sheu JY, Lin TH. Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem. 1999;32:131–136.CrossRefPubMedGoogle Scholar
  28. 28.
    Samir M, el Kholy NM. Thiobarbituric acid reactive substances in patients with laryngeal cancer. Clin Otolaryngol Allied Sci. 1999;24:232–234.CrossRefPubMedGoogle Scholar
  29. 29.
    Schmelz EM, Sullards MC, Dillehay DL, et al. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. J Nutr. 2000;130:522–527.CrossRefPubMedGoogle Scholar
  30. 30.
    Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Bio Med. 1997;22:749–760.CrossRefGoogle Scholar
  31. 31.
    Meister A. New aspects of glutathione biochemistry and transport-selective alteration of glutathione metabolism. Nutr Rev. 1984;42:397–410.CrossRefPubMedGoogle Scholar
  32. 32.
    Kullisaar T, Songisepp E, Mikelsaar M, et al. Antioxidative probiotic fermented goats’ milk decreases oxidative stress-mediated atherogenicity in human subjects. Br J Nutr. 2003;90:449–456.CrossRefPubMedGoogle Scholar
  33. 33.
    Farag IM, Abdel-Aziz KB, Nada SA, et al. Modulation of ochratoxin-induced oxidative stress, genotoxicity and spermatotoxic alterations by Lactobacillus rhamnosus GG in male albino mice. J Am Sci. 2010;6:575–587.Google Scholar
  34. 34.
    Kyle ME, Miccadei S, Nakae D, et al. Superoxide dismutase and catalase protect cultured hepatocytes from the cytotoxicity of acetaminophen. Biochem Biophys Res Commun. 1987;149:889–896.CrossRefPubMedGoogle Scholar
  35. 35.
    Matés JM, Sánchez-Jiménez F. Antioxidant enzymes and their implications in pathophysiologic processes. Front Biosci. 1999;4:D339–D345.CrossRefPubMedGoogle Scholar
  36. 36.
    Yasuda E, Serata M, Sako T. Suppressive effect on activation of macrophages by Lactobacillus casei strain Shirota genes determining the synthesis of cell wall-associated polysaccharides. Appl Environ Microbiol. 2008;74:4746–4755.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Mikelsaar M, Zilmer M. Lactobacillus fermentum ME-3—an antimicrobial and antioxidative probiotic. Microb Ecol Health Dis. 2009;21:1–27.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bruno-Bárcena JM, Andrus JM, Libby SL, et al. Expression of a heterologous manganese superoxide dismutase gene in intestinal lactobacilli provides protection against hydrogen peroxide toxicity. Appl Environ Microbiol. 2004;70:4702–4710.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Shen H, Tsuchida S, Tamai K, et al. Identification of cysteine residues involved in disulfide formation in the inactivation of glutathione transferase P-form by hydrogen peroxide. Arch Biochem Biophys. 1993;300:137–141.CrossRefPubMedGoogle Scholar
  40. 40.
    Gregor R, Andrew WB. Selection of lactobacillus strains for urogenital probiotic applications. J Infect Dis. 2001;183:S77–S80.CrossRefGoogle Scholar
  41. 41.
    Manju V, Balasubramaniyan V, Nalini N. Rat colonic lipid peroxidation and antioxidant status: the effects of dietary luteolin on 1, 2-dimethylhydrazine challenge. Cell Mol Biol Lett. 2005;10:535–551.PubMedGoogle Scholar
  42. 42.
    Payne D, Kubes P. Nitric oxide donors reduce the rise in reperfusion-induced intestinal mucosal permeability. Am J Physiol. 1993;265:G189–G190.PubMedGoogle Scholar
  43. 43.
    Kumar M, Kumar A, Nagpal R, et al. Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr. 2010;61:473–496.CrossRefPubMedGoogle Scholar
  44. 44.
    Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998;12:2973–2983.CrossRefPubMedGoogle Scholar
  45. 45.
    Lohrum MA, Vousden KH. Regulation and activation of p53 and its family members. Cell Death Differ. 1999;6:1162–1168.CrossRefPubMedGoogle Scholar
  46. 46.
    Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114:4139–4140.PubMedGoogle Scholar
  47. 47.
    Hilska M, Collan YU, Laine VJO, et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum. 2005;48:2197–2208.CrossRefPubMedGoogle Scholar
  48. 48.
    Resnick MB, Routhier J, Konkin T, et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069–3075.CrossRefPubMedGoogle Scholar
  49. 49.
    Merino D, Malkin D. p53 and hereditary cancer. Subcell Biochem. 2014;85:1–16.CrossRefPubMedGoogle Scholar
  50. 50.
    Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–299.CrossRefPubMedGoogle Scholar
  52. 52.
    Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA. 1995;92:7834–7838.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem. 1997;272:31482–31488.CrossRefPubMedGoogle Scholar
  54. 54.
    Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA. 1996;3:14559–14563.CrossRefGoogle Scholar
  55. 55.
    Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998;423:275–280.CrossRefPubMedGoogle Scholar
  56. 56.
    Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Sohini Walia
    • 1
  • Rozy Kamal
    • 2
  • D. K. Dhawan
    • 3
  • S. S. Kanwar
    • 1
    Email author
  1. 1.Department of MicrobiologyCSK Himachal Pradesh Agricultural UniversityPalampurIndia
  2. 2.Centre for Nuclear MedicinePanjab UniversityChandigarhIndia
  3. 3.Department of BiophysicsPanjab UniversityChandigarhIndia

Personalised recommendations